<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="102419">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01785160</url>
  </required_header>
  <id_info>
    <org_study_id>1220.65</org_study_id>
    <secondary_id>2012-004872-21</secondary_id>
    <nct_id>NCT01785160</nct_id>
  </id_info>
  <brief_title>Investigation of Faldaprevir Effect on Pharmacokinetics of Raltegravir</brief_title>
  <official_title>Investigation of Faldaprevir Effect on Steady State Pharmacokinetics of Raltegravir in Healthy Male and Female Volunteers (an Open-label Trial With Two Periods in a Fixed Sequence)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this trial is to investigate effect of faldaprevir on steady state
      pharmacokinetics of raltegravir.

      The assessment of safety and tolerability will be an additional objective of this trial.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Area under the concentration-time curve of the analyte in plasma at steady state over the uniform dosing interval t</measure>
    <time_frame>up to 132 hours</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum measured concentration of the analyte in plasma at steady state over the uniform dosing interval t</measure>
    <time_frame>up to 132 hours</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Raltegravir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>coated tablets, oral administration with 240 ml water</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Raltegravir + Faldaprevir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>coated tablets and soft gelatine capsule, oral administration with 240 ml water</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltegravir</intervention_name>
    <description>low dose oral administration</description>
    <arm_group_label>Raltegravir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltegravir</intervention_name>
    <description>low dose oral administration</description>
    <arm_group_label>Raltegravir + Faldaprevir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Faldaprevir</intervention_name>
    <description>medium dose oral administration</description>
    <arm_group_label>Raltegravir + Faldaprevir</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        1. healthy male subjects

        Exclusion criteria:

        1. Any relevant deviation from healthy conditions
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1220.65.1 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 10, 2013</lastchanged_date>
  <firstreceived_date>December 13, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
